Access To Advanced Health Institute

Infectious Disease Research Institute

University System of Maryland

University of Virginia Patent Foundation

Christopher B Fox

Neal Van Hoeven

Amit Praful Khandhar

Susan S Lin

Steven G Reed

Darrick Carter

Thomas S Vedvick

Marc B Taraban

William A Petri

Yihua (Bruce) Yu

Anwar Ahniyaz

Mark T Orr

Mayuresh M Abhyankar

Jesse Erasmus

Reinhard Vehring

Susan Baldwin

Traci Mikasa

Jesse H Erasmus

Nicholas Carrigy

Mellissa Gomez

Mani Ordoubadi

Ryan Kramer

Michelle Archer

Lucien Barnes V

Ryan M Kramer

V Lucien Barnes

Stable aqueous formulations of adjuvant comprising a TLR7/8 agonist or a TLR4 agonist with a helper lipid that are adsorbed to alum are provided. Compositions and methods of using the formulations for stimulating an immune response are also provided.

Formulation containing TLR agonist and methods of use

Provided herein are nanoalum particles comprising an aluminum salt and a sizing agent, wherein the size of the particle ranges from about 1 nm to 450 nm. Such a nanoalum particles are stable and are amenable to a terminal sterilization step prior to vialing. Compositions comprising the nanoalum particles, and the making and using of the nanoalum particles are also provided.

Nanoalum particles containing a pegylated lipid sizing agent

The invention provides for thermostable spray dried formulations including vaccines and pharmaceutical compositions for inducing or enhancing an immune response and methods of use thereof. The spray dried formulations are a dry powder generally comprising an antigen and/or an adjuvant, a metabolizable oil, and one or more excipients.

Composition and method for spray drying an adjuvant vaccine emulsion

Provided herein are PEGylated liposomes, and methods of making and using thereof. The PEGylated liposomes comprise at least a cholesterol, a non-PEGylated neutral lipid, and a PEGylated lipid, wherein the average molecular weight of the PEG component in the PEGylated lipid is about 5000 Daltons or less. The PEGylated liposomes are stable and capable of delivery of an agent for the generation of an immune response, for example an agent for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the PEGylated liposomes and using the PEGylated liposomes for stimulating an immune response are also provided.

Pegylated liposomes and methods of use

This disclosure describes the use of solanesol as an adjuvant in vaccine compositions, as well as related prophylactic and therapeutic methods. Solanesol may be used to replace squalene in vaccine compositions with similar or superior immunostimulatory effects. Solanesol, which is solid at room temperature, may be formulated for use in vaccine compositions by heating above its melting temperature in an aqueous solution to form a dispersion.

Solanesol vaccine adjuvants and methods of preparing same

Provided herein are nanostructured lipid carrier compositions, and methods of making and using thereof. The compositions comprise a nanostructured lipid carrier (NLC), where the NLC comprises an oil core comprising a mixture of a liquid phase lipid and a solid phase lipid, a cationic lipid, a sorbitan ester, and a hydrophilic surfactant, and optionally a bioactive agent. The bioactive agent can be associated with the NLC. The compositions are capable of delivery of a biomolecule to a cell for the generation of an immune response, for example, for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the compositions and using the compositions for stimulating an immune response are also provided.

Nanostructured lipid carriers and stable emulsions and uses thereof

A method of using the transverse relaxation rate (R) of solvent NMR signal to noninvasively assess if an alum-containing product, such as a vaccine, has been acceptably resuspended for use following transport and/or storage. This technique allows for the manufacturer and/or distributor and/or end user to monitor for unexpected stressors associated with transport and/or storage including, but not limited to, temperature fluctuations, pH changes, vigorous shaking during transportation, exposure to sunlight, and freezing.

In situ determination of acceptable resuspension in pharmaceutical products using water proton NMR

The invention provides for thermostable lyophilized formulations, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response, and methods of use thereof. The lyophilized formulations generally comprise an antigen and/or an adjuvant, a metabolizable oil, and a cake-forming excipient.

Single vial vaccine formulations

A method of using the transverse relaxation rate (R) of solvent NMR signal to noninvasively assess alum-containing products such as vaccines. This technique can be used for quality control in vaccine manufacturing (e.g., fill-finish step) to determine the evenness of alum filling level as well as extent of alum particle sedimentation in filled and sealed products.

In situ determination of alum filling evenness and sedimentation in pharmaceutical products using water proton NMR

Formulations and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed. The formulations generally comprise a TLR4 agonist and a metabolizable oil at a concentration of about 0.01%-1% v/v, wherein the hydrophobic:lipophilic balance (HLB) of the emulsion is greater than about 9.

Adjuvant formulations comprising TLR4 agonists and methods of using the same

PEGylated liposomes and methods of use

Provided herein are nanoalum particles comprising an aluminum salt and a sizing agent, wherein the size of the particle ranges from about 1 nm to 450 nm. Such nanoalum particles are stable and are amenable to a terminal sterilization step prior to vialing. Compositions comprising the nanoalum particles, and the making and using of the nanoalum particles are also provided.

Growing community of inventors

Sumner, WA, United States of America

Christopher B Fox